Avivia

What Avivia does

Avivia BV is a pharmaceutical contract development organization (CDO) headquartered at the Novio Tech Campus in Nijmegen, Netherlands, founded in 2005. The firm operates as a CMO-independent development partner that transforms active pharmaceutical ingredients into drug products through formulation development, analytical R&D, predictive and biorelevant dissolution testing (USP apparatus I-IV), and small-scale GMP production covering extrusion, spray-drying, nano-milling, tabletting, encapsulation, aseptic filling and lyophilisation. Two proprietary platforms — Excipia (excipient characterization and quality assurance) and Siloxia (silica-based formulation technologies) — are productised as distinct sub-brands alongside the core formulation services for complex NCEs, value-added generics and branded product life-cycle management.

The firm serves a horizontal mix of buyers including Big Pharma, specialty pharma, generic drug manufacturers, emerging drug developers, universities, excipient manufacturers, law firms and VC investors, with operations spanning Europe and broader EMEA. Its technology platform combines conventional analytical instrumentation (chromatography, spectroscopy, mass spectrometry) with proprietary excipient and dissolution expertise, supported by 30+ granted patents across the team and experience on 120+ unique molecules. A team of approximately 10 specialised professionals, each with 20-25+ years of industry experience drawn from Synthon, Encapson and other pharma backgrounds, delivers these services.

Avivia generates revenue primarily on a fee-for-service basis for standalone projects, with full development programs also offered under co-development arrangements at cost-price plus a single success-driven milestone and small royalty. Projects are structured in phases with explicit go/no-go decision points. Following a management buyout in June 2024 and the appointment of Lee Ayres as Managing Director in March 2024, Avivia was acquired by Ofichem Group in July 2025, integrating it into a European-centred CDMO platform that spans drug substance, formulation development and GMP manufacturing.

Name

Avivia

Legal name

Avivia BV

Website

https://avivia.nl

Company type

Private

Founded year

2005

Operating status

Acquired

Headcount range

11–50 employees

Short description

Avivia BV is a Netherlands-based pharmaceutical contract development organization offering formulation development, analytical R&D, biorelevant dissolution testing, and excipient characterization (Excipia platform) to Big Pharma, specialty pharma, generic, and emerging drug developers globally, with a team of ~10 specialists.

Ownership category

akta.pro rank

Product category

Pharmaceutical R&D Services (Contract Development Organization)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Pharmaceutical formulation development
• Analytical R&D services
• Dissolution testing
• Excipient characterization
• Generic drug development

Headquarters

HQ city

Nijmegen

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Fee-for-service pharmaceutical development: Full development projects performed on a pure fee-for-service basis or through co-development where services are provided at cost-price with a single success-driven milestone payment and small royalty payment. Stand-alone project services always performed on fee-for-service basis.
2. Co-development partnerships: Co-development arrangements where Avivia provides services at cost-price and includes a single success-driven milestone payment plus small royalty payment for full development projects.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Avivia is a pharmaceutical contract development organization (CDO) that transforms active pharmaceutical ingredients (APIs) into drug products through formulation development, analytical R&D, predictive dissolution testing, and excipient characterization. The company offers integrated drug development services spanning value-added generics, life cycle management of branded products, and complex CMC development of new chemical entities, supported by small-scale GMP production capabilities.

Product overview

Avivia is a pharmaceutical development organization (CDO/CDMO) offering an integrated portfolio of pharmaceutical R&D services rather than a single software product. The core offerings include Pharmaceutical Formulation Development (transforming APIs into drug products), Analytical R&D Services (characterization and method development), Predictive and Biorelevant Dissolution Testing, and the Excipia excipient characterization platform. Services span from early feasibility phases through GMP manufacturing, supporting value-added generics, branded product life cycle management, and complex NCE formulation development. The company operates small-scale GMP production capabilities and maintains CMO independence to select optimal manufacturing partners.

Differentiator

Problem solved

Functional benefit

Brands

• Excipia: An excipient characterisation and research service platform focused on excipient quantification and ensuring excipients are of the right quality. Uses proprietary expertise and state-of-the-art facilities to physicochemically characterize excipients, identify critical functional attributes, and guarantee the stability and efficacy of drug products.
• Siloxia

Products and services

• Pharmaceutical Formulation Development

Quantifiable outcome

• 120+ unique molecules worked on across pharmaceutical development programs
• +2 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Recipharm: European-headquartered CDMO offering formulation development and GMP manufacturing across multiple dosage forms; regional incumbent competing for the same pharma formulation engagements.
• Lonza: Global CDMO offering small-molecule drug substance and drug product services including formulation development; competing incumbent across the full pharma value chain.
• Cambrex: Small-molecule API and drug product CDMO with strong formulation development and analytical services; relevant broad incumbent comparator for Avivia's drug-product CDMO positioning.
• Catalent: Global CDMO with extensive small-molecule drug product formulation, softgel, and oral solid dose capabilities; competes with Avivia for Big Pharma formulation work at much larger scale.
• Eurofins CDMO: Eurofins division providing contract development and manufacturing services for pharma, including formulation and analytical support comparable to Avivia's portfolio.

Regional players

• Colorcon: Global excipient and film-coating supplier offering formulation development support and technical services — adjacent peer to Avivia's excipient characterization and solid-dose formulation work.

Direct peers

• Ardena: Netherlands/Belgium-based formulation development and analytical CDMO serving small and mid-sized pharma with similar drug-product development, analytical, and GMP-support capabilities as Avivia.
• Quotient Sciences: UK-based CDMO specializing in formulation development, drug product manufacturing, and clinical testing — directly comparable to Avivia's complex-formulation, generic-development, and lifecycle-management positioning.
• Ofichem Group: Acquirer of Avivia and integrated CDMO offering drug substance and drug product services with GMP-certified operations in Ter Apel and Leiden; direct overlap in formulation development and GMP manufacturing.
• DFE Pharma: Netherlands-based excipient manufacturer and development partner; directly adjacent to Avivia's Excipia excipient characterization platform and serves overlapping customers in formulation development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/avivia_bv
• Facebookfacebook.com/AviviaBV
• LinkedInlinkedin.com/company/10099859

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avivia